Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.63 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28975910 | 0.93 | TYK2 (0.73) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL24498074 | 0.88 | TYK2 (0.55) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL29686651 | 0.88 | TYK2 (0.55) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL30553623 | 0.88 | TYK2 (0.57) | TYK2JAK1JAK2 | |
| SCHEMBL29043542 | 0.88 | TYK2 (0.57) | TYK2JAK1JAK2 | |
| SCHEMBL25536922 | 0.87 | TYK2 (0.56) | TYK2JAK2 | |
| SCHEMBL30392752 | 0.85 | TYK2 (0.63) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL30393144 | 0.85 | TYK2 (0.63) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL24899888 | 0.85 | TYK2 (0.63) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL25537143 | 0.84 | TYK2 (0.70) | TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | TYK2 2/4885JAK1 11/4885CYP2C19 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.